Sign In
Buy HOWL
$0.362
-0.0084 (-2.27%)
At Close: Jun 23, 2026
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
08:00am, Tuesday, 04'th Mar 2025
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the developmen
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
07:30am, Monday, 24'th Feb 2025
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeuti
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
08:00am, Monday, 13'th Jan 2025
– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways –
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
08:00am, Wednesday, 20'th Nov 2024
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
09:02am, Thursday, 07'th Nov 2024
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
09:00am, Friday, 04'th Oct 2024
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
09:17am, Thursday, 08'th Aug 2024
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.14 per share a year ago.
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
07:05am, Thursday, 08'th Aug 2024
– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting –
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data fo
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy -
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
08:00am, Thursday, 30'th May 2024
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers -
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
07:00am, Friday, 03'rd May 2024
— Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO —
Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors
First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werew
